Royalty Pharma declares a Q1 2026 dividend of $0.235 per Class A share, a 6.8% increase from the previous quarter.
Quiver AI Summary
Royalty Pharma plc announced a dividend of $0.235 per Class A ordinary share for the first quarter of 2026, marking a 6.8% increase from the previous quarter. The dividend is set to be paid on March 10, 2026, to shareholders on record as of February 20, 2026. Established in 1996, Royalty Pharma is a leading buyer of biopharmaceutical royalties and a supporter of innovation within the industry, collaborating with various organizations from academia to major pharmaceutical companies. The company’s substantial portfolio includes royalties from over 35 commercial products and 19 development-stage candidates, with notable therapies such as Vertex's Trikafta, Johnson & Johnson's Tremfya, and Biogen's Spinraza. For further details, visit their website.
Potential Positives
- The declaration of a $0.235 dividend per Class A ordinary share demonstrates the company's financial strength and commitment to returning value to shareholders.
- A 6.8% increase in the quarterly dividend from the previous quarter indicates positive growth and confidence in future earnings.
- The company's extensive portfolio of royalties, including over 35 commercial products, highlights its strategic position within the biopharmaceutical industry and potential for continued revenue generation.
Potential Negatives
- None
FAQ
What is the latest dividend declared by Royalty Pharma?
Royalty Pharma has declared a dividend of $0.235 per Class A ordinary share for the first quarter of 2026.
When will the dividend be paid to shareholders?
The dividend will be paid on March 10, 2026, to shareholders of record on February 20, 2026.
How much has the dividend increased compared to the previous quarter?
The dividend has increased by 6.8% over the previous quarter's dividend.
What role does Royalty Pharma play in the biopharmaceutical industry?
Royalty Pharma is the largest buyer of biopharmaceutical royalties and funds innovation within the industry.
What types of products does Royalty Pharma's portfolio include?
The portfolio includes royalties on over 35 commercial products and 19 development-stage product candidates.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RPRX Insider Trading Activity
$RPRX insiders have traded $RPRX stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $RPRX stock by insiders over the last 6 months:
- GEORGE W. LLOYD (EVP, Investments & CLO) has made 0 purchases and 11 sales selling 355,426 shares for an estimated $13,807,997.
- TERRANCE P. COYNE (EVP & CFO) has made 0 purchases and 12 sales selling 347,922 shares for an estimated $13,534,004.
- MARSHALL URIST (EVP, Research & Investments) has made 0 purchases and 7 sales selling 143,151 shares for an estimated $5,607,685.
- GREGORY NORDEN sold 33,500 shares for an estimated $1,213,748
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RPRX Revenue
$RPRX had revenues of $609.3M in Q3 2025. This is an increase of 7.9% from the same period in the prior year.
You can track RPRX financials on Quiver Quantitative's RPRX stock page.
$RPRX Hedge Fund Activity
We have seen 289 institutional investors add shares of $RPRX stock to their portfolio, and 186 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 25,441,140 shares (-69.9%) from their portfolio in Q3 2025, for an estimated $897,563,419
- FMR LLC removed 12,371,107 shares (-30.7%) from their portfolio in Q3 2025, for an estimated $436,452,654
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 5,965,633 shares (+99.4%) to their portfolio in Q3 2025, for an estimated $210,467,532
- CAPITAL INTERNATIONAL INVESTORS added 5,332,074 shares (+24.4%) to their portfolio in Q3 2025, for an estimated $188,115,570
- VIKING GLOBAL INVESTORS LP removed 2,597,460 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $91,638,388
- JUPITER ASSET MANAGEMENT LTD removed 2,470,706 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $87,166,507
- MORGAN STANLEY removed 2,440,149 shares (-5.2%) from their portfolio in Q3 2025, for an estimated $86,088,456
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RPRX Analyst Ratings
Wall Street analysts have issued reports on $RPRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 10/10/2025
- Goldman Sachs issued a "Buy" rating on 09/30/2025
To track analyst ratings and price targets for $RPRX, check out Quiver Quantitative's $RPRX forecast page.
$RPRX Price Targets
Multiple analysts have issued price targets for $RPRX recently. We have seen 4 analysts offer price targets for $RPRX in the last 6 months, with a median target of $43.5.
Here are some recent targets:
- Steve Scala from TD Cowen set a target price of $45.0 on 12/11/2025
- Terence Flynn from Morgan Stanley set a target price of $54.0 on 10/10/2025
- Asad Haider from Goldman Sachs set a target price of $42.0 on 09/30/2025
- Geoff Meacham from Citigroup set a target price of $42.0 on 07/22/2025
Full Release
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company’s quarterly dividend over the previous quarter’s dividend.
The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, among others, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com .
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
[email protected]
